Amarin (AMRN)
(Delayed Data from NSDQ)
$0.87 USD
+0.01 (1.72%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.90 +0.03 (2.87%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth C Momentum C VGM
Brokerage Reports
Amarin Corporation PLC [AMRN]
Reports for Purchase
Showing records 141 - 160 ( 353 total )
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare- Yas'' Weekly Recap of Our Key Notes and Upcoming Events
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Encouraged by Reiterated 2020 Revenue Guidance and Vascepa Commercial Outlook; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
As we are three weeks away from JPM Healthcare conference.
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Vascepa FDA-Approval for Expanded Label in CV Risk Reduction Consistent With Our Label Expectations; Reit Buy and $51 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Company: Amarin Corporation PLC
Industry: Medical - Biomedical and Genetics
Upon Closer Look, What Does EVAPORATE Tell Us?
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y